Seven Healthcare Industry "High Reliability Organization Champions" Recognized by Patient Safety Movement Foundation
10.11.2021 16:00:00 EET | Business Wire | Press release
Medical errors claim the lives of nearly three million individuals across the globe every year. In any other high-risk industry, like aviation and nuclear power, these numbers would not be acceptable. Yet, the healthcare industry has continued to allow these events to occur—putting patients and staff at risk. The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, believes that to reach this goal healthcare organizations that provide care to patients need to commit to operating as highly reliable organizations (HROs) to reduce preventable medical harm. To support this, PSMF launched its new HRO Champion Program and is excited to recognize the first seven healthcare organizations that have committed to this effort. These HRO Champions include: Kaiser Permanente Northern California, Parrish Medical Center (Titusville, Fla.), Hospital Puebla (Puebla, Mexico), Hospitales Star Medica (Mexico City, Mexico), Hospital Materno Infantil Irapuato (Irapuato, Mexico), Hospital de Especialidades Pediatrico Leon (San Jose del Potrero, Mexico) and Hospital Español (Granada, Mexico).
“The pandemic exposed gaps in the global healthcare system, which forced us to examine the processes in place and identify ways we can prioritize patient safety,” stated Dr. Mike Ramsay, CEO of PSMF. “We are proud to recognize and unite healthcare systems that share this mission and provide them resources to help improve their processes and eliminate preventable harm in their organizations.”
The new HRO Champions program puts an emphasis on data transparency, as this is a critical component to achieving zero harm and improving patient safety. To participate, hospitals and healthcare organizations commit to sharing their adverse event and near-miss data, once annually, to measure the impact of improvements in the network over time. Not only does transparency hold health systems accountable, but it also makes it easier for patients to access safety information to make informed healthcare decisions.
“We are honored to have been designated as HRO Champions by the Patient Safety Movement Foundation, in which we have found a valuable ally to continue improving our care processes,” stated Jose Testas Anton, vice president of Hospital Español. “At Hospital Español, we believe that being able to share and collaborate with other health systems and provide information related to patient safety outside the walls of our organization will help generate collaborative learning and promote patient safety around the world.”
“We are pleased to be recognized for our unwavering commitment to provide safe and reliable patient care and commend our staff for being strong advocates for and partnering with their patients to prevent unnecessary harm,” said Robin Betts, vice president of safety, quality and regulatory services for Kaiser Permanente Northern California. “Our hospitals are among the country’s highest performing for minimizing patient injuries, medication errors and infections. We have processes in place, which closely align with the Patient Safety Movement Foundation to highlight potential safety issues for our care teams who focus every day on protecting the health of their patients, keeping them safe from harm and providing the highest quality care.”
By committing to zero harm, healthcare organizations are eligible for many different benefits, including free coaching, workshops, publicity and other tools. HRO Champions are announced every month and can submit data any time throughout the year to be eligible. Learn more about how to become a HRO Champion: https://patientsafetymovement.org/take-action/organizational-action/going-above-and-beyond/hro-champions/
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005553/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
